NCT07489612

QLS1410 in Participants With Uncontrolled Hypertension

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 260 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Conditions

• Hypertension (HTN)

Interventions

Type	Name	Description
DRUG	Dose 1 of QLS1410	QLS1410 tablet administered orally, once daily (QD).
DRUG	Dose 2 of QLS1410	QLS1410 tablet administered orally, once daily (QD).
DRUG	Dose 3 of QLS1410	QLS1410 tablet administered orally, once daily (QD).
DRUG	placebo	Matching placebo tablet administered orally, once daily (QD).

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-12-01
• Completion: 2027-03-01
• First posted: 2026-03-24
• Last updated: 2026-03-24